- Home
- SILC vs MOLN Comparison
SILC vs MOLN Comparison
Compare SILC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SILC | MOLN |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 144.0M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SILC | MOLN |
|---|---|---|
| Price | $29.56 | $4.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 41.1K | 1.9K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.85 | $3.36 |
| 52 Week High | $29.61 | $5.36 |
Technical Indicators
Market Signals| Indicator | SILC | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 82.36 | 49.35 |
| Support Level | $17.75 | $4.04 |
| Resistance Level | N/A | $4.50 |
| Average True Range (ATR) | 1.56 | 0.16 |
| MACD | 0.71 | 0.03 |
| Stochastic Oscillator | 90.43 | 66.78 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.